Last reviewed · How we verify

NCT04416022

Cervical Gland Area as a Predictor of Success of Labour Induction

Status unknown Last updated 4 June 2020
What this trial tests

trial testing Ultrasound examination in Induced Vaginal Delivery in 100 participants. Status unknown.

Timeline
7 June 2020
Primary endpoint
7 June 2022
7 June 2022

Quick facts

Lead sponsorRambam Health Care Campus
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment100
Start date7 June 2020
Primary completion7 June 2022
Estimated completion7 June 2022

Drugs / interventions tested

Conditions studied

Sponsor

Rambam Health Care Campus — full company profile →

Who can join

Adults 18 to 45, female only, with Induced Vaginal Delivery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Women who fulfil the inclusion criteria and who are planned for labour induction will be recruited. Bishop score, cervical length, and the presence of cervical glandular area (CGA) will be documented for every patient up to 12 hours prior to the induction process, and patient information and maternal and neonatal outcome will be documented following the delivery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ultrasound examination

Trials testing the same drug.

Other Rambam Health Care Campus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04416022.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing